CST-2032 and CST-107 for Dementia

Phase 2

Recruiting

Research Sponsored by CuraSen Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline after 14 days of treatment

Summary

This trial is testing two drugs, CST-2032 and CST-107, to see if they can help people with early memory and thinking problems. The drugs aim to improve brain cell function or protect them, potentially improving memory and thinking skills.

Eligible Conditions

Mild Cognitive Impairment
Dementia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline after 14 days of treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline after 14 days of treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline after 14 days of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Electrocardiograms (ECGs)

Treatment-emergent adverse events

Vital Signs

Secondary study objectives

Change from Baseline in CANTAB Adaptive Tracking Task

Change from Baseline in CANTAB Paired Associates Learning Test

Change from Baseline in CANTAB Rapid Visual Information Processing

+4 more

Trial Design

4Treatment groups

Experimental Treatment

Group I: Placebo to CST-2032 (6mg)/CST-107 (3mg)Experimental Treatment1 Intervention

Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days.

Group II: Placebo to CST-2032 (3mg)/CST-107 (3mg)Experimental Treatment1 Intervention

Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days.

Group III: CST-2032 (6mg)/CST-107 (3mg) to PlaceboExperimental Treatment1 Intervention

Subjects will receive daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.

Group IV: CST-2032 (3mg)/CST-107 (3mg) to PlaceboExperimental Treatment1 Intervention

Subjects will receive daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.

Do I qualify?Apply below to find out